Our CST scientists work at the bench daily to produce and validate your antibodies. They have hands-on knowledge of each antibody's performance. These same scientists provide technical support and assistance.
General Manager of Cell Signaling Technology China, Jay Dong, is Elected Co-President of Chinese Society for Cell Biology’s Academia-Industry Consortium for Innovation and Entrepreneurship
Danvers, MA – November 2, 2017 – Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, has announced that Jay Dong, General Manager of its China operations, has been elected Co-President of the Chinese Society for Cell Biology’s Academia-Industry Consortium for Innovation and Entrepreneurship. This consortium was formed to support translation of basic research into translational medicine. Dong was inaugurated by Dr. Yeguang Chen, President of Chinese Society for Cell Biology (CSCB) at CSCB 2017 Conference in Xiamen, China.
As one of the leading industry representatives in the consortium, CST will be an active participant, providing support to local scientists and sharing the company’s experience in moving basic research findings from the bench to the clinic. During the conference, Dong described how CST scientists identified an ALK mutation in non-small cell lung cancer using proprietary PTMScan® technology. This CST discovery has been translated into several companion diagnostic assays used to identify patients that may respond to certain therapeutics for treating non-small cell lung cancer.
"China now ranks among the top nations in the annual quantity and quality of papers published internationally," said Jay Dong during his inaugural speech. "However, our mission right now is to translate scientific findings into therapeutics that have the potential to aid humankind. The major mission of the consortium is to build a cooperative, complementary relationship between academia and industry, so they can empower the advancement of translational medicine together. There is no easy path or shortcut to translational science, but through cooperation, we can be both small enough to be effective and large enough to be impactful. As for CST, we want to empower scientists to translate their innovative ideas into clinical solutions."
"Science and business working together benefits all of us, as business brings the experience of turning discoveries into practical realities. We all have the aim of innovating for the benefit of patients and eliminating disease, and we can coordinate our strengths to this result," said Christopher Budde, Chief Commercial Officer and Head of Global Operations of CST.
"To empower, enable scientists around the world to conduct innovative, translational research is part of our CST mission", commented Michael Comb, CEO of CST.
About Cell Signaling Technology
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing the world’s highest quality, innovative, research and diagnostic products to accelerate biological understanding and enable personalized medicine. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.
Rebecca J. Reppucci
Cell Signaling Technology, Inc.
Director of Marketing Communications
About the Chinese Society for Cell Biology
Founded in 1980, the Chinese Society for Cell Biology (CSCB) is one of the leading scientific organizations in China. With over 10,000 members, CSCB is home to scientists, as well as teachers and students in cell biology. CSCB is dedicated to facilitate learning and innovation through conferences and journals, promote research collaborations, provide training opportunities to students and young scientists, and educate the general public in cell biology and biomedicine.